US drugmaker expects to manufacture 3bn doses of vaccine with BioNTech this year
The US drugmaker Pfizer has lifted its 2021 forecast for revenues from its Covid vaccine to $36bn (£26.3bn), and forecast another $29bn sales next year after it started shipping booster jabs and shots for children.
The Covid jab, called Comirnaty and developed with Germany’s BioNTech, contributed $13bn of revenues in the three months to 30 September. That was more than half of Pfizer’s total revenues of $24bn in the quarter, which rose 134% from a year earlier. In the first six months of the year, Corminaty revenues were $11.3bn.
Read the original article at The Guardian